ArticleCurrent medicinal chemistry2026
Unveiling the Small Molecules Binding Site of CD36 Cell Surface Receptor Through Docking and Molecular Dynamics Simulations.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCD36 is a transmembrane glycoprotein involved in lipid uptake and signal transduction, playing a crucial role in various physiological and pathological processes. Structurally, it is composed primarily of an ectodomain (residues 30-439), which is essential for ligand binding and facilitating Long-Chain Fatty Acid (LCFA) uptake. Two lysine residues (K164 and K166) have been proposed to contribute significantly to LCFA internalization. Elucidating the ligand-binding cavities within CD36 can provide structural insights that may serve as a foundation for drug design.
methodsIn this study, we employed a combination of molecular docking, molecular dynamics simulations, and cavity-detection algorithms to investigate the structural basis of CD36 interactions with small molecules and fatty acids.
resultsWe identified three main ligand-binding regions: a primary LCFA-binding cavity, a secondary LCFA-binding cavity, and a Small-Molecule Acceptor Cavity (SMAC). We evaluated three derivatives of the N-(2-hydroxy-4,6-dimethoxybenzylidene)acetohydrazide scaffold (AP5055, AP5156, and AP5258), two polyphenolic compounds (Puerarin and Salvianolic acid), and two well-known CD36 inhibitors (SSO and MTN). DISCUSSION: Our findings implicate residues K334, E335, and R337 in disrupting LCFA uptake, while residues T195, L200, F201, Y202, P203, T207, A208, D209, Y230, and K231 delineate the initial segment of the SMAC.
conclusionThis study highlights critical residues and structural features involved in ligand recognition by CD36. The identification of the SMAC and its role in modulating LCFA uptake provides promising insights for the development of therapeutic agents targeting CD36-related pathologies, including cancer, diabetes, and metabolic disorders.
Indexed as
Identifiers
41764615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.